By Brazil Stock Guide – Fleury S.A. (B3: FLRY3) has approved the acquisition of 100% of the quotas of LSL – Laboratório de Análises Clínicas Ltda., a diagnostics company operating in Rio Claro and Santa Gertrudes, in São Paulo’s interior. LSL generated R$24 million in revenue in the 12 months ended May 2025, the company said in its market statement.
The board approved the transaction unanimously, noting that the acquisition does not fall under the provisions of Article 256 of Brazil’s Corporate Law, which means no shareholder approval or withdrawal rights are required.
With three service units focused on clinical testing and vaccination, LSL strengthens Fleury’s presence across mid-sized cities in São Paulo state, reinforcing the company’s strategy of regional capillarity and portfolio diversification. The move follows Fleury’s merger with Grupo Hermes Pardini, which created one of Latin America’s largest integrated diagnostic platforms.
The deal fits into Fleury’s broader plan to expand beyond Brazil’s major capitals and compete with peers such as Dasa (B3: DASA3) and Alliar (B3: AALR3), as well as emerging digital health networks. While the value of the acquisition was not disclosed, the transaction reflects Fleury’s disciplined approach to small, high-return acquisitions that enhance operating efficiency and proximity to patients — focusing on scalability, technology, and capital discipline.